Literature DB >> 29741783

Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice.

Ghasem Ghalamfarsa1, Ali Rastegari2,3, Fatemeh Atyabi3, Hadi Hassannia4,5, Mohammad Hojjat-Farsangi6,7, Amir Ghanbari1, Enayat Anvari8, Jamshid Mohammadi9, Gholamreza Azizi10, Ali Masjedi11,12, Mehdi Yousefi2, Bahman Yousefi11, Jamshid Hadjati13, Farhad Jadidi-Niaragh11,12,13.   

Abstract

CD73 facilitates tumor growth by upregulation of the adenosine (immunosuppressive factor) in the tumor microenvironment, however, its precise molecular mechanisms is not precisely understood. Regarding the importance of angiogenesis in tumor development and spreading, we decided to assign the anti-angiogenic effects of CD73 suppression. We used chitosan lactate (ChLa) nanoparticles (NPs) to deliver CD73-specific small interfering RNA (siRNA) into cancer cells. Our results showed that treatment of the 4T1 cells with CD73-specific siRNA-loaded NPs led to potent inhibition of cancer cell proliferation and cell cycle arrest, in vitro. This growth arrest was correlated with downregulation of angiogenesis-related molecules including vascular endothelial growth factor (VEGF)-A, VEGF-R2, interleukin (IL)-6, and transforming growth factor (TGF)-β. Moreover, administration of NPs loaded with CD73-siRNA into 4T1 breast cancer-bearing mice led to tumor regression and increased mice survival time accompanied with downregulation of angiogenesis (VEGF-A, VEGF-R2, VE-Cadherin, and CD31) and lymphangiogenesis (VEGF-C and LYVE-1)-related genes in the tumor site. Furthermore, the expression of angiogenesis promoting factors including IL-6, TGF-β, signal transducer, and activator of transcription (STAT)3, hypoxia inducible factor (HIF)-1α, and cyclooxygenase (COX)2 was decreased after the CD73 suppression in mice. Moreover, analysis of leukocytes derived from the tumor samples, spleen, and regional lymph nodes showed that they had lower capability for secretion of angiogenesis promoting factors after CD73-silencing. These results indicate that suppression of tumor development by downregulation of CD73 is in part related to angiogenesis arrest. These findings imply a promising strategy for inhibiting tumor growth accompanied with suppressing the angiogenesis process.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD73; adenosine; angiogenesis; breast cancer; nanoparticle; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29741783     DOI: 10.1002/jcp.26743

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

Review 1.  Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.

Authors:  Quoc-Viet Le; Juhan Suh; Yu-Kyoung Oh
Journal:  AAPS J       Date:  2019-05-17       Impact factor: 4.009

2.  Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.

Authors:  Armin Mahmoud Salehi Kheshti; Farnaz Hajizadeh; Asal Barshidi; Bentolhoda Rashidi; Farbod Ebrahimi; Simin Bahmanpour; Vahid Karpisheh; Fatemeh Karimian Noukabadi; Fariba Karoon Kiani; Hadi Hassannia; Fatemeh Atyabi; Seyed Hossein Kiaie; Fatah Kashanchi; Jamshid Gholizadeh Navashenaq; Hamed Mohammadi; Rafieh Bagherifar; Reza Jafari; Naime Majidi Zolbanin; Farhad Jadidi-Niaragh
Journal:  Pharm Res       Date:  2022-02-15       Impact factor: 4.200

3.  A Crucial Angiogenesis-Associated Gene MEOX2 Could Be a Promising Biomarker Candidate for Breast Cancer.

Authors:  Huxia Wang; Yanan Tang; Xiaomin Yang; Weiyi Wang; Pihua Han; Jing Zhao; Sai He; Peijun Liu
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

4.  Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.

Authors:  Hadi Hassannia; Mitra Ghasemi Chaleshtari; Fatemeh Atyabi; Mahshid Nosouhian; Ali Masjedi; Mohammad Hojjat-Farsangi; Afshin Namdar; Gholamreza Azizi; Hamed Mohammadi; Ghasem Ghalamfarsa; Gholamabas Sabz; Sajad Hasanzadeh; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Immunology       Date:  2019-10-24       Impact factor: 7.397

5.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

Review 6.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 7.  Targeting the purinergic pathway in breast cancer and its therapeutic applications.

Authors:  Julia Beatrice de Araújo; Vanessa Vitória Kerkhoff; Sarah Franco Vieira de Oliveira Maciel; Débora Tavares de Resende E Silva
Journal:  Purinergic Signal       Date:  2021-02-12       Impact factor: 3.765

Review 8.  Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals.

Authors:  Alam Zeb; Isra Rana; Ho-Ik Choi; Cheol-Ho Lee; Seong-Woong Baek; Chang-Wan Lim; Namrah Khan; Sadia Tabassam Arif; Najam Us Sahar; Arooj Mohsin Alvi; Fawad Ali Shah; Fakhar Ud Din; Ok-Nam Bae; Jeong-Sook Park; Jin-Ki Kim
Journal:  Pharmaceutics       Date:  2020-12-06       Impact factor: 6.321

Review 9.  Targeting CD73 to augment cancer immunotherapy.

Authors:  Meejeon Roh; Derek A Wainwright; Jennifer D Wu; Yong Wan; Bin Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-08-07       Impact factor: 5.547

10.  CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.

Authors:  Hidenori Tsukui; Hisanaga Horie; Koji Koinuma; Hideyuki Ohzawa; Yasunaru Sakuma; Yoshinori Hosoya; Hironori Yamaguchi; Kotaro Yoshimura; Alan Kawarai Lefor; Naohiro Sata; Joji Kitayama
Journal:  BMC Cancer       Date:  2020-05-12       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.